Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1004 (IMP1707) monotherapy in advanced solid tumors
CTR20251737Phase 2Active
- Sponsor
- IMPACT Therapeutics
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EIK1004 in Nonhematologic neoplasms, sponsored by IMPACT Therapeutics. Started May 2025; status: active.
02
Drugs
EIK1004
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251737.